Kristof Vercruysse on ”First in Human” Presented at ASH25
Kristof Vercruysse, CEO and Co-Founder at TargED Biopharmaceuticals, reposted from TargED Biopharmaceuticals on LinkedIn:
”Back in town from ASH25.
What a journey and emotional rollercoaster it has been the last days.
Thanks to the full TargED team to make the First in Human happen with positive results and looking forward for more to come.”
Quoting TargED Biopharmaceuticals‘s post:
”We are excited to announce positive results from a Phase 1 study for TargED’s lead investigational thrombolytic fusion protein, TGD001, in an oral presentation at ASH25 in Orlando, Florida today.
The first-in-human clinical trial demonstrated that TGD001 is safe and was well tolerated with no spontaneous bleeding events across four ascending dose cohorts.
TargED Biopharmaceuticals plans to initiate two Phase 1/2 clinical proof-of-concept studies evaluating TGD001 as a potential treatment for patients with acute ischemic stroke (AIS) and thrombotic microangiopathies (TMAs), including immune thrombotic thrombocytopenic purpura (iTTP).
Read the full press release with detailed results.
Stay updated with Hemostasis Today.
-
Jun 26, 2026, 06:01Nicolas Hubacz: A Sharper Look at the Brain’s Vascular Landscape
-
Jun 26, 2026, 05:57Ayse Bahar Keleşoğlu Dinçer: New Insights into Antiphospholipid Syndrome Classification and Recurrent Thrombosis Risk
-
Jun 26, 2026, 05:55Shinya Goto: How Newton’s Laws Shape Platelet Function
-
Jun 26, 2026, 05:50Andrew Emad: Five Years of Partnership, Innovation, and Impact at Africa Health ExCon 2026
-
Jun 26, 2026, 05:48Regan Bucciol: The Emerging Role of Erythrocytes in Thrombosis
-
Jun 26, 2026, 05:26Maxime Dely: Strengthening Skills in Plasma and Red Cell Exchange
-
Jun 26, 2026, 05:26Andreas Calatzis: Hidden Differences in Anti-Xa Testing
-
Jun 26, 2026, 04:56Recognizing the 2026 ISTH Fundamental Research Career Development Award Recipients
-
Jun 26, 2026, 04:42Jonathan James: Amplifying Voices Across the Bleeding Disorders Community